drugset / Trial / NCT00856583
Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of the study is to determine whether there is an increased all-cause mortality in sertindole-treated patients in comparison to patients treated with a well-known antipsychotic (risperidone) when used under normal marketed conditions in the treatment of schizophrenia.
Timeline
- Start
- 2002-07
- Primary completion
- 2008-02
- Completion
- 2008-02
Publications
- Results Peuskens J, Tanghoj P, Mittoux A; Sertindole Cohort. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology. Pharmacoepidemiol Drug Saf. 2008 May;17(5):425-33. doi: 10.1002/pds.1594.
- Results Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, Le Jeunne C, Naber D, Priori S, Sturkenboom M, Thibaut F, Peuskens J, Mittoux A, Tanghoj P, Toumi M, Moore ND, Mann RD. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand. 2010 Nov;122(5):345-55. doi: 10.1111/j.1600-0447.2010.01563.x.
- Results Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, Hall GC, Le Jeunne C, Mittoux A, Peuskens J, Priori S, Sturkenboom M, Thomas SH, Tanghoj P, Toumi M, Mann R, Moore ND. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol. 2010 Dec;20(12):829-38. doi: 10.1016/j.euroneuro.2010.09.001.
- Results De Hert M, Mittoux A, He Y, Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci. 2011 Jun;261(4):231-9. doi: 10.1007/s00406-010-0142-x. Epub 2010 Sep 5.
- Results De Hert M, Mittoux A, He Y, Peuskens J. A head-to-head comparison of sertindole and risperidone on metabolic parameters. Schizophr Res. 2010 Nov;123(2-3):276-7. doi: 10.1016/j.schres.2010.07.030. Epub 2010 Aug 21. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Risperidone | Other / unclassified | 1 mg | — |
| Comparator | Risperidone | Other / unclassified | 2 mg | — |
| Comparator | Risperidone | Other / unclassified | 3 mg | — |
| Comparator | Risperidone | Other / unclassified | 4 mg | — |
| Comparator | Risperidone | Other / unclassified | 8 mg | — |
| Subject | Sertindole | Small molecule | 4 mg | — |
| Subject | Sertindole | Small molecule | 12 mg | — |
| Subject | Sertindole | Small molecule | 16 mg | — |
| Subject | Sertindole | Small molecule | 20 mg | — |
| Subject | Sertindole | Small molecule | 24 mg | — |